Skip to main content

AgomAb Therapeutics NV

AGMB
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0002020932

In the last 90 days, AgomAb Therapeutics NV insiders filed 7 open-market purchases and 0 sales; 34 institutions reported holding it in 13F filings for Q2 2026, worth $337.0M in total; no superinvestor holds it.

Source
SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
Updated
Oct 8, 2026, 3:14 PM ET

No financial statements

AgomAb Therapeutics NV has no financial statements on Livermore. They come from the XBRL data in 10-K, 10-Q, 20-F and 40-F filings, so ETFs, funds and companies that don't file these reports have none.